Efficacy, tolerability, and safety of Efsubaglutide Alfa in participants with obesity or overweight ( LIGHT 1): A randomized, double‐blind, placebo‐controlled, ascending‐dose phase 2a trial
Authors' conclusion
Efsubaglutide Alfa demonstrated significant weight-loss efficacy, metabolic improvements, and a preferable tolerability and safety profile, supporting further clinical development for obesity and related metabolic disorders.
Study context
- Population
- Overweight and obese individuals unresponsive to lifestyle interventions; mean age 36.3 years, bodyweight 92.9 kg, BMI 33.0 kg/m²randomized 8:2
- Participants
- 50 participants
- Comparison
- Once-weekly subcutaneous Efsubaglutide Alfa vs placebo
- Primary endpoint
- Percentage change in body weight from baseline and proportion achieving ≥5% weight loss
Methodological detailsmulticenter, double-blind, placebo-controlled, multiple-ascending dose, phase 2a, Randomized 25 April 2024 to 18 November 2024
- Multicenter
- Double-blind
- Placebo-controlled
- Multiple-ascending dose
- Phase 2a
- Randomized 25 April 2024 to 18 November 2024
Primary result
As reported in the abstract
Percentage change in body weight from baseline
Percentage change in body weight from baseline Efsubaglutide Alfa mean 7.16% (95% CI −8.08–-6.24) · Placebo 0.86%
Achieved ≥5% weight loss
Secondary outcomes
Body composition with Efsubaglutide Alfa · from baseline
- Fat mass decrease
- 4.47 kg
- Lean mass decrease
- 2.00 kg
- Lean-to-fat mass ratio improvement
- 19.73 percentage points
Metabolic measures
- BMI, waist circumference, and systolic blood pressure significantly decreased
Safety
- Treatment-related serious adverse events
- 0
- Gastrointestinal AEs most common, mostly mild to moderate, mainly during dose escalation
Original publication
Efficacy, tolerability, and safety of Efsubaglutide Alfa in participants with obesity or overweight ( LIGHT 1): A randomized, double‐blind, placebo‐controlled, ascending‐dose phase 2a trial. Diabetes Obes Metab. Published 6 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →